Skip to main content
John Kane, MD, Psychiatry, Glen Oaks, NY, Long Island Jewish Medical Center

JohnMichaelKaneMD

Psychiatry Glen Oaks, NY

Psychopharmacology

Professor, The Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research. Vice President, Behavioral Health Services, Northwell Health. Chairman, Department of Psychiatry, The Zucker Hillside Hospital. Chair & Professor, Psychiatry, Hofstra Northwell School of Medicine. Professor, Molecular Medicine, Hofstra Northwell School of Medicine.

Dr. Kane is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kane's full profile

Already have an account?

Summary

  • Dr. John Kane is a psychiatrist in Glen Oaks, NY and is affiliated with multiple hospitals in the area, including Long Island Jewish Medical Center, Glen Cove Hospital, and The Zucker Hillside Hospital. He received his medical degree from NYU Grossman School of Medicine and has been in practice 46 years. He specializes in psychopharmacology and is experienced in bipolar disorder, depression, schizophrenia, mood disorders, and anxiety disorders.

Education & Training

  • Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside Hospital
    Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalResidency, Psychiatry, 1971 - 1975
  • New York University School of Medicine
    New York University School of MedicineClass of 1971

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1972 - 2025
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia  
    John M Kane, Eric D Achtyes, Delbert G Robinson, JAMA Psychiatry
  • Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel Dataset  
    John Kane, MD, JMIR Medical Education
  • Disturbing Lack of Early Intervention Studies in Bipolar Disorder—Reply  
    John Kane, MD, JAMA
  • Join now to see all

Authored Content

  • Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase SchizophreniaJuly 2020
  • Examining Predictors of Real-World User Engagement with Self-Guided eHealth Interventions: Analysis of Mobile Apps and Websites Using a Novel DatasetDecember 2018

Press Mentions

  • Teva to Present Data Demonstrating UZEDYtm (Risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association's 2023 Annual Meeting
    Teva to Present Data Demonstrating UZEDYtm (Risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association's 2023 Annual MeetingMay 22nd, 2023
  • Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
    Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective DisorderMay 9th, 2023
  • New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
    New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with SchizophreniaOctober 30th, 2021
  • Join now to see all

Hospital Affiliations